Core Insights - Alumis Inc. has promoted Sanam Pangali to Chief Legal Officer and Corporate Secretary, succeeding Sara Klein who has retired [1][2] - Sanam Pangali has a strong background in legal and business roles, previously serving as Senior Vice President, Legal at Alumis and holding leadership positions at ACELYRIN, Inc. and other biopharmaceutical companies [2] - Alumis is focused on developing next-generation targeted therapies for immune-mediated diseases, with a pipeline that includes oral tyrosine kinase 2 inhibitors and anti-insulin-like growth factor 1 receptor therapy [3] Company Overview - Alumis is a late-stage biopharma company dedicated to improving patient health outcomes in immune-mediated diseases [3] - The company utilizes a proprietary data analytics platform to develop its therapies, which include ESK-001 for systemic immune-mediated disorders and A-005 for neuroinflammatory diseases [3] - The pipeline also features lonigutamab for thyroid eye disease and several preclinical programs identified through a precision approach [3]
Alumis Announces the Promotion of Sanam Pangali to Chief Legal Officer and Corporate Secretary